Wolfe Downgrades Pfizer Stock to Underperform on Lingering COVID Risk
0h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Wolfe Research announced on 16 May 2026 that it downgraded Pfizer Inc. (PFE) from Peer Perform to Underperform. The firm highlighted persistent uncertainty around long-term demand for COVID-19 related products as the primary driver, citing a potential multi-billion dollar annual revenue headwind. The downgrade follows a prolonged period of consolidation for the pharmaceutical giant's stock, which has underperformed the S&P 500 Health Care sector index by over 15 percentage points year-to-date.
The COVID-19 pandemic propelled Pfizer to record revenue of $100.3 billion in 2022, with its Comirnaty vaccine and Paxlovid antiviral generating nearly $57 billion combined that year. The subsequent revenue cliff has been stark, with COVID product sales contracting to approximately $12.5 billion in 2025. The current downgrade reflects a reassessment of this product segment's baseline, transitioning from a windfall to a volatile, endemic revenue stream that complicates financial forecasting.
This backdrop coincides with a wider market recalibration of pandemic winners. The broader Health Care Select Sector SPDR Fund (XLV) has gained 4.2% year-to-date, while Pfizer shares have declined 8.1% over the same period. The catalyst for Wolfe's action is the firm's analysis suggesting that consensus estimates for Pfizer's 2027 and 2028 earnings remain too optimistic, failing to fully price in the structural decline and ongoing demand volatility for its COVID portfolio.
Pfizer's stock closed at $24.71 on 15 May, the day preceding the downgrade. This price represents a 52-week decline of 22% from its high of $31.69. The company's forward price-to-earnings ratio of 12.5x sits at a 30% discount to its 5-year historical average of 17.8x. Wolfe's report estimates the lingering COVID uncertainty poses a $4 to $5 billion annual revenue risk to Pfizer's future financial performance.
A comparison of key valuation metrics against a close peer, Merck & Co. (MRK), illustrates the discount. Merck trades at a forward P/E of 18.2x and has a 2026 revenue growth consensus estimate of +6.5%. Pfizer's consensus revenue growth for 2026 is projected at -2.1%. The firm's market capitalization of $139.5 billion is now less than half its late-2021 peak of over $335 billion.
| Metric | Pfizer (PFE) | Merck (MRK) |
|---|---|---|
| Forward P/E Ratio | 12.5x | 18.2x |
| 2026 Revenue Growth Est. | -2.1% | +6.5% |
| Div. Yield (approx.) | 6.1% | 2.4% |
The downgrade signals a sector-wide shift towards penalizing companies with overconcentration in waning pandemic products. This could pressure other vaccine-focused names like Moderna (MRNA) and Novavax (NVAX), which face similar demand normalization. Conversely, firms with diversified portfolios and strong non-COVID pipelines, such as Eli Lilly (LLY) and Novo Nordisk (NVO), may continue to attract capital as safe havens within the sector.
A counter-argument to Wolfe's thesis is that Pfizer's deep valuation discount and near 6.1% dividend yield already reflect these risks, providing a margin of safety for income-focused investors. However, the risk of a dividend cut, while not Wolfe's base case, becomes more plausible if COVID revenues deteriorate faster than expected. Positioning data indicates institutional investors have been net sellers of PFE for seven consecutive quarters, with flow rotating into healthcare service providers and medical device makers like UnitedHealth Group (UNH) and Medtronic (MDT).
Investors should monitor Pfizer's Q2 2026 earnings report, scheduled for 30 July 2026, for updated management guidance on COVID product sales and pipeline milestones. Key technical levels for the stock include a major support zone between $23.50 and $24.00, a level last tested in late 2023. A decisive break below could signal a test of the $21.50 low.
The next significant catalyst is the FDA's Prescription Drug User Fee Act (PDUFA) action date of 22 October 2026 for Pfizer's ulcerative colitis drug etrasimod. Positive regulatory news could partially offset negative sentiment from the COVID portfolio. Market participants will also watch the 10-year Treasury yield, currently at 4.35%; a sustained move above 4.5% would increase pressure on high-dividend, slower-growth stocks like Pfizer.
An Underperform rating is an analyst's recommendation that a stock is expected to trail the average return of its sector or the broader market over the next 12-18 months. For retail holders, it signals that professional analysts see more downside risk than upside potential. It does not necessarily mean 'sell immediately,' but it suggests reviewing the investment thesis, especially if one's thesis relied on a COVID revenue rebound that analysts now doubt.
The current situation echoes the 2008-2012 period when Pfizer faced the expiration of patents for blockbusters like Lipitor. During that cliff, Pfizer's revenue fell from $67.8 billion in 2010 to $51.6 billion in 2012, a 24% drop. Analysts issued similar downgrades based on looming revenue gaps. The key difference is that the COVID revenue decline was much steeper and faster, but the underlying challenge of replacing massive lost income remains a comparable strategic hurdle for the company.
Pfizer's dividend yield of approximately 6.1% is high relative to both the S&P 500 average and its pharmaceutical peers. A yield this elevated often reflects market skepticism about its sustainability. The dividend's safety hinges on the performance of Pfizer's non-COVID business and its new product launches. Wolfe's analysis implies risk, but a cut is not their base case. Investors should watch the company's free cash flow generation, which must comfortably cover the $9 billion annual dividend payout.
Wolfe's downgrade underscores that Pfizer's transition from pandemic windfall to sustainable growth remains incomplete and fraught with multi-billion dollar revenue uncertainty.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.